A bid by Eli Lilly ( LLY) to get Gemzar approved for ovarian cancer came up short when an advisory panel of the Food and Drug Administration recommended against the expanded use. The panel, voting in Washington on Monday, polled 9 to 2 against Gemzar, which is already approved as a treatment for pancreatic and lung cancer. Lilly wanted the drug approved for ovarian cancer in combination with carboplatin, another ovarian-cancer treatment. Gemzar is sometimes prescribed off-label for ovarian cancer. Still, panel members weren't persuaded by clinical data that Lilly claimed showed the drug was statistically effective in treating the disease. While the full FDA isn't bound by its panels' recommendations, it usually follows them. Shares of Lilly closed at $57.24 Monday and were down nearly 3% in the after-hours session.